Egypt Diabetes Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Egypt Diabetes Drugs Market is Segmented Into Drugs (insulin Drugs (basal or Long-Acting Insulins, Bolus or Fast-Acting Insulins, Traditional Human Insulins, And Biosimilar Insulins), Oral Anti-Diabetic Drugs (Biguanides, Alpha-glucosidase Inhibitors, Dopamine D2 Receptor Agonist, Sglt-2 Inhibitors, Dpp-4 Inhibitors, Sulfonylureas, And Meglitinides), Non-insulin Injectable Drugs (GLP-1 Receptor Agonists and Amylin Analogue), And Combination Drugs (insulin Combinations and Oral Combinations)). The Market Provides the Value (in USD) for the Above-Mentioned Segments.

Egypt Diabetes Drugs Market Size

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
View Global Report
Egypt Diabetes Drugs Market Summary
Study Period 2018 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
Market Size (2024) USD 414.66 Million
Market Size (2029) USD 480.70 Million
CAGR (2024 - 2029) 3.00 %

Major Players

Egypt Diabetes Drugs Market Major Players

*Disclaimer: Major Players sorted in no particular order

setting-icon

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Egypt Diabetes Drugs Market Analysis

The Egypt Diabetes Drugs Market size is estimated at USD 414.66 million in 2024, and is expected to reach USD 480.70 million by 2029, growing at a CAGR of 3% during the forecast period (2024-2029).

Diabetic drugs are medicines developed to stabilize and control blood glucose levels amongst people with diabetes. Diabetic drugs are commonly used to manage diabetes. Diabetic drugs have been potential candidates for treating diabetic patients affected by SARS-CoV-2 infection during the COVID-19 pandemic.

Egypt is the ninth country in terms of Diabetes prevalence worldwide. Currently, as per IDF, about 18.4% of the adult population in Egypt has diabetes. More than 11% of the Egyptian population suffers from diagnosed Type-2 diabetes according to Egypt Youth Association for Health Development. 73 million adults (20-79) are living with diabetes in the IDF MENA Region in 2021. This figure is estimated to increase to 95 million by 2030. 

Diabetes is associated with many health complications. Patients with diabetes require many corrections throughout the day to maintain nominal blood glucose levels, such as administering additional insulin or ingesting additional carbohydrates by monitoring their blood glucose levels. Diabetes poses an emerging healthcare burden across the country and is one of the leading causes of premature death, morbidity, and loss of economic growth.

Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.

Egypt Diabetes Drugs Market Trends

The oral anti-diabetic drugs segment holds the highest market share in the Egypt Diabetes Drugs Market in the current year

The oral anti-diabetic drugs segment holds the highest market share of about 88.8% in the Egypt Diabetes Drugs Market in the current year.

Oral Anti-Diabetic Drugs are available internationally and are recommended for use when escalation of treatment for type 2 diabetes is required along with lifestyle management. Oral agents are typically the first medications used in treating type 2 diabetes due to their wide range of efficacy, safety, and mechanisms of action. 

Anti-diabetic drugs help diabetes patients control their condition and lower the risk of diabetes complications. People with diabetes may need to take anti-diabetic drugs for their whole lives to control their blood glucose levels and avoid hypoglycemia and hyperglycemia. Oral anti-diabetic agents present the advantages of easier management and lower cost. So they became an attractive alternative to insulin with better acceptance, which enhances adherence to the treatment.

In July 2022, Zydus Lifesciences announced that it had received final approval to market Empagliflozin and Metformin Hydrochloride tablets in multiple strengths. Empagliflozin and Metformin Hydrochloride tablets are used with proper diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. They are also used to lower the risk of cardiovascular death in patients with type 2 diabetes mellitus and established cardiovascular disease.

The Egyptian Government launched the '100 million Seha' initiative, which seeks to screen Egyptians for non-communicable diseases like diabetes. Various healthcare companies announced their collaboration with the Egypt Ministry of Health to promote the initiative. Such initiatives are expected to create awareness among the people regarding monitoring and controlling diabetes, thereby enhancing the market prospects in the coming years.

Egypt Diabetes Drugs Market - Type-2 Diabetes Population in million, 2017-2022

Metformin is expected to dominate the Egypt Diabetes Drugs Market over the forecast period

Metformin is expected to dominate the Egypt Diabetes Drugs Market and register a CAGR of around 1.5% over the forecast period.

Biguanides are a class of medications used to treat type 2 diabetes. They work by reducing the production of glucose that occurs during digestion. Metformin is the only biguanide currently available in most countries for treating diabetes. Glucophage (metformin) and Glucophage XR (metformin extended release) are well-known brand names for these drugs. Others include Fortamet, Glumetza, and Riomet. Metformin is also available in combination with several other types of diabetes medications, such as sulfonylureas.

Diabetes reduces lifespan, and people with the disease are likely to experience blindness and be hospitalized for amputations, kidney failure, heart attacks, strokes, and heart failure. Metformin is the first-line choice for the management of hyperglycemia in T2DM. Besides being an important glucose-lowering agent, metformin also includes significant anti-inflammatory properties. Other options must be considered when metformin is contraindicated or not tolerated or when treatment goals are not achieved after three months of use at the maximum tolerated dose. Dipeptidyl peptidase-4 inhibitors, sodium-glucose cotransporter-2 inhibitors, and glucagon-like peptide-1 agonists are generally used to supplement treatment with metformin.

In Egypt, the social level plays an important role in patients' access to health care. The number of healthcare centers, hospitals, and pharmacies is very low in rural areas compared to big cities and urban areas. The financial level is a major determinant of people's access to health care, as the salaries of most employees in Egypt are not enough to afford their monthly diabetes supplies. 

For students and school children with type 1 diabetes, the National Health Insurance System covers insulin, and the student pays nothing for NPH, mixed and short-acting insulins, and only 60% of the price of other types of insulin, which are usually unavailable in the pharmacies of the National Health Insurance System. However, the government is working in the direction of improving the access of patients through various initiatives.

Egypt Diabetes Drugs Market - Volume CAGR (%), by Drugs, 2023-2028

Egypt Diabetes Drugs Industry Overview

The Egypt Diabetes Drugs Market is consolidated, with major manufacturers, namely Eli Lilly, Sanofi, Novo Nordisk, AstraZeneca, and other generic players holding a presence in the region. A major share of the market is held by manufacturers concomitant with strategy-based M&A operations and constantly entering the market to generate new revenue streams and boost existing ones.

Egypt Diabetes Drugs Market Leaders

  1. AstraZeneca

  2. Boehringer Ingelheim

  3. Novo Nordisk A/S

  4. Sanofi Aventis

  5. Eli Lilly and Company

*Disclaimer: Major Players sorted in no particular order

Egypt Diabetes Drugs Market Concentration
Need More Details on Market Players and Competitors?
Download PDF

Egypt Diabetes Drugs Market News

  • Novmber 2023: Novo Nordisk's initiation of a Phase III comparative trial for their pipeline drug CagriSema against the recently approved Zepbound suggests the potential for direct competition between the two drugs upon Novo Nordisk's candidate entering the market.
  • October 2022: The Ministry of Industry and Advanced Technology announced the signing of a pair of memoranda of understanding worth AED 260 million (USD 70.8 million) between major pharmaceutical and medical device companies in the UAE. The partnerships align with the National Strategy for Industry and Advanced Technology and the ICV Program. It aims to attract investors and manufacturers to the UAE's pharmaceutical and medical equipment sectors. Under a separate MoU, PureHealth, and Gulf Pharmaceutical Industries Company will establish the first factory in the Middle East to produce Glargine to treat diabetes.

Egypt Diabetes Drugs Market Report - Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

    3. 4.3 Market Restraints

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Bargaining Power of Suppliers

      2. 4.4.2 Bargaining Power of Consumers

      3. 4.4.3 Threat of New Entrants

      4. 4.4.4 Threat of Substitute Products and Services

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 Insulins

      1. 5.1.1 Basal or Long Acting Insulins

        1. 5.1.1.1 Lantus (Insulin Glargine)

        2. 5.1.1.2 Levemir (Insulin Detemir)

        3. 5.1.1.3 Toujeo (Insulin Glargine)

        4. 5.1.1.4 Tresiba (Insulin Degludec)

        5. 5.1.1.5 Basaglar (Insulin Glargine)

      2. 5.1.2 Bolus or Fast Acting Insulins

        1. 5.1.2.1 NovoRapid/Novolog (Insulin Aspart)

        2. 5.1.2.2 Humalog (Insulin Lispro)

        3. 5.1.2.3 Apidra (Insulin Glulisine)

      3. 5.1.3 Traditional Human Insulins

        1. 5.1.3.1 Novolin/Actrapid/Insulatard

        2. 5.1.3.2 Humulin

        3. 5.1.3.3 Insuman

      4. 5.1.4 Biosimilar Insulins

        1. 5.1.4.1 Insulin Glargine Biosimilars

        2. 5.1.4.2 Human Insulin Biosimilars

    2. 5.2 Oral Anti-diabetic drugs

      1. 5.2.1 Biguanides

        1. 5.2.1.1 Metformin

      2. 5.2.2 Alpha-Glucosidase Inhibitors

        1. 5.2.2.1 Alpha-Glucosidase Inhibitors

      3. 5.2.3 Dopamine D2 receptor agonist

        1. 5.2.3.1 Bromocriptin

      4. 5.2.4 SGLT-2 inhibitors

        1. 5.2.4.1 Invokana (Canagliflozin)

        2. 5.2.4.2 Jardiance (Empagliflozin)

        3. 5.2.4.3 Farxiga/Forxiga (Dapagliflozin)

        4. 5.2.4.4 Suglat (Ipragliflozin)

      5. 5.2.5 DPP-4 inhibitors

        1. 5.2.5.1 Onglyza (Saxagliptin)

        2. 5.2.5.2 Tradjenta (Linagliptin)

        3. 5.2.5.3 Vipidia/Nesina(Alogliptin)

        4. 5.2.5.4 Galvus (Vildagliptin)

      6. 5.2.6 Sulfonylureas

        1. 5.2.6.1 Sulfonylureas

      7. 5.2.7 Meglitinides

        1. 5.2.7.1 Meglitinides

    3. 5.3 Non-Insulin Injectable drugs

      1. 5.3.1 GLP-1 receptor agonists

        1. 5.3.1.1 Victoza (Liraglutide)

        2. 5.3.1.2 Byetta (Exenatide)

        3. 5.3.1.3 Bydureon (Exenatide)

        4. 5.3.1.4 Trulicity (Dulaglutide)

        5. 5.3.1.5 Lyxumia (Lixisenatide)

      2. 5.3.2 Amylin Analogue

        1. 5.3.2.1 Symlin (Pramlintide)

    4. 5.4 Combination drugs

      1. 5.4.1 Insulin combinations

        1. 5.4.1.1 NovoMix (Biphasic Insulin Aspart)

        2. 5.4.1.2 Ryzodeg (Insulin Degludec and Insulin Aspart)

        3. 5.4.1.3 Xultophy (Insulin Degludec and Liraglutide)

      2. 5.4.2 Oral Combinations

        1. 5.4.2.1 Janumet (Sitagliptin and Metformin)

  6. 6. MARKET INDICATORS

    1. 6.1 Type-1 Diabetic Population

    2. 6.2 Type-2 Diabetic Population

  7. 7. COMPETITIVE LANDSCAPE

    1. 7.1 COMPANY PROFILES

      1. 7.1.1 Novo Nordisk A/S

      2. 7.1.2 Takeda

      3. 7.1.3 Pfizer

      4. 7.1.4 Eli Lilly

      5. 7.1.5 Janssen Pharmaceuticals

      6. 7.1.6 Astellas

      7. 7.1.7 Boehringer Ingelheim

      8. 7.1.8 Merck and Co.

      9. 7.1.9 AstraZeneca

      10. 7.1.10 Bristol Myers Squibb

      11. 7.1.11 Julphar

      12. 7.1.12 Novartis

      13. 7.1.13 Sanofi Aventis

    2. *List Not Exhaustive
    3. 7.2 COMPANY SHARE ANALYSIS

      1. 7.2.1 Novo Nordisk A/S

      2. 7.2.2 Sanofi Aventis

      3. 7.2.3 Eli Lilly

      4. 7.2.4 Merck and Co.

      5. 7.2.5 Others

  8. 8. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Egypt Diabetes Drugs Industry Segmentation

Diabetes Drugs are used to manage diabetes mellitus by lowering the glucose level in the blood. The Egypt Diabetes Drugs Market is segmented into drugs. The report offers the value (in USD) and volume (in units) for the above segments.

Insulins
Basal or Long Acting Insulins
Lantus (Insulin Glargine)
Levemir (Insulin Detemir)
Toujeo (Insulin Glargine)
Tresiba (Insulin Degludec)
Basaglar (Insulin Glargine)
Bolus or Fast Acting Insulins
NovoRapid/Novolog (Insulin Aspart)
Humalog (Insulin Lispro)
Apidra (Insulin Glulisine)
Traditional Human Insulins
Novolin/Actrapid/Insulatard
Humulin
Insuman
Biosimilar Insulins
Insulin Glargine Biosimilars
Human Insulin Biosimilars
Oral Anti-diabetic drugs
Biguanides
Metformin
Alpha-Glucosidase Inhibitors
Alpha-Glucosidase Inhibitors
Dopamine D2 receptor agonist
Bromocriptin
SGLT-2 inhibitors
Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Farxiga/Forxiga (Dapagliflozin)
Suglat (Ipragliflozin)
DPP-4 inhibitors
Onglyza (Saxagliptin)
Tradjenta (Linagliptin)
Vipidia/Nesina(Alogliptin)
Galvus (Vildagliptin)
Sulfonylureas
Sulfonylureas
Meglitinides
Meglitinides
Non-Insulin Injectable drugs
GLP-1 receptor agonists
Victoza (Liraglutide)
Byetta (Exenatide)
Bydureon (Exenatide)
Trulicity (Dulaglutide)
Lyxumia (Lixisenatide)
Amylin Analogue
Symlin (Pramlintide)
Combination drugs
Insulin combinations
NovoMix (Biphasic Insulin Aspart)
Ryzodeg (Insulin Degludec and Insulin Aspart)
Xultophy (Insulin Degludec and Liraglutide)
Oral Combinations
Janumet (Sitagliptin and Metformin)
Need A Different Region Or Segment?
Customize Now

Egypt Diabetes Drugs Market Research FAQs

The Egypt Diabetes Drugs Market size is expected to reach USD 414.66 million in 2024 and grow at a CAGR of 3% to reach USD 480.70 million by 2029.

In 2024, the Egypt Diabetes Drugs Market size is expected to reach USD 414.66 million.

AstraZeneca, Boehringer Ingelheim, Novo Nordisk A/S, Sanofi Aventis and Eli Lilly and Company are the major companies operating in the Egypt Diabetes Drugs Market.

In 2023, the Egypt Diabetes Drugs Market size was estimated at USD 402.22 million. The report covers the Egypt Diabetes Drugs Market historical market size for years: 2018, 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Egypt Diabetes Drugs Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.

Egypt Diabetes Drugs Industry Report

Statistics for the 2024 Egypt Diabetes Drugs market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Egypt Diabetes Drugs analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!

Egypt Diabetes Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)